Evidence map›Paper›PMID 32824376›Full record

ArticleBiomolecules2020

The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin.

Line K Skaanning, Angelo Santoro, Thomas Skamris, Jacob Hertz Martinsen, Anna Maria D'Ursi, Saskia Bucciarelli, Bente Vestergaard, Katrine Bugge, Annette Eva Langkilde, Birthe B Kragelund

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Neurons and Glia Interplay in α-Synucleinopathies.International journal of molecular sciences · 2021
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Line K SkaanningDepartment of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.ORCID 0000-0002-7679-6143
Angelo SantoroStructural Biology and NMR Laboratory, Department of Biology, University of Copenhagen, Ole Maaløes vej 5, 2200 Copenhagen N, Denmark.
Thomas SkamrisDepartment of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Jacob Hertz MartinsenDepartment of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.ORCID 0000-0001-9874-1138
Anna Maria D'UrsiDepartment of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.
Saskia BucciarelliDepartment of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.ORCID 0000-0001-7612-223X
Bente VestergaardDepartment of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Katrine BuggeStructural Biology and NMR Laboratory, Department of Biology, University of Copenhagen, Ole Maaløes vej 5, 2200 Copenhagen N, Denmark.ORCID 0000-0002-6286-6243
Annette Eva LangkildeDepartment of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.ORCID 0000-0003-2467-4205
Birthe B KragelundStructural Biology and NMR Laboratory, Department of Biology, University of Copenhagen, Ole Maaløes vej 5, 2200 Copenhagen N, Denmark.ORCID 0000-0002-7454-1761
University of Copenhagen · DKUniversity of Salerno · IT

Funding

Lundbeckfonden BrainstrucNovo Nordisk Fonden #NNF15OC0016670Villum Fonden Instrument grant
6 · The paper itself

Abstract

The intrinsically disordered protein α-synuclein (aSN) is, in its fibrillated state, the main component of Lewy bodies-hallmarks of Parkinson's disease. Additional Lewy body components include glycosaminoglycans, including heparan sulfate proteoglycans. In humans, heparan sulfate has, in an age-dependent manner, shown increased levels of sulfation. Heparin, a highly sulfated glycosaminoglycan, is a relevant mimic for mature heparan sulfate and has been shown to influence aSN fibrillation. Here, we decompose the underlying properties of the interaction between heparin and aSN and the effect of heparin on fibrillation. Via the isolation of the first 61 residues of aSN, which lacked intrinsic fibrillation propensity, fibrillation could be induced by heparin, and access to the initial steps in fibrillation was possible. Here, structural changes with shifts from disorder via type I β-turns to β-sheets were revealed, correlating with an increase in the aSN

Indexed as

alpha-SynucleinBinding SitesCircular DichroismHeparinHumansMicroscopy, FluorescenceModels, MolecularProtein BindingProtein DomainsProtein Structure, Secondaryalpha-SynucleinHeparinbindingfibrillationheparinIDPintrinsically disordered proteinsNMRParkinson’s diseaseSAXStype I β-turnα-synuclein

Identifiers

PMID32824376
PMCPMC7464290
OpenAlexW3049109523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.